Thoratec Loan Facility UpdateFramingham, MA and Sydney,...

Thoratec Loan Facility Update
Framingham, MA and Sydney, Australia, January 4, 2010 On December 17, 2009,
HeartWare delivered to Thoratec Corporation (Thoratec) a borrowing request in relation to the
existing US$20 million credit facility which was available to HeartWare under the Loan
Agreement (the Loan Agreement) with Thoratec, dated as of February 12, 2009. Pursuant to
the borrowing request, HeartWare requested a draw down of US$16 million (the December
2009 loan), noting that US$4 million had previously been drawn and repaid to Thoratec. In
accordance with the Loan Agreement, this amount was delivered to HeartWare immediately
prior to Christmas.
On December 29, 2009, HeartWare repaid the December 2009 Loan in full, in accordance with
the terms of the Loan Agreement. Following this repayment, all outstanding principal amounts
of the loans to HeartWare (i.e. US$20 million), including any accrued and unpaid interest, as
well as any amounts in the escrow account that may have been borrowed under the Loan
Agreement have been borrowed and repaid in full. Pursuant to the terms of the Loan Agreement,
amounts paid in respect of any loans may not be reborrowed by HeartWare. As a consequence
of the repayment of the December 2009 Loan, any right of Thoratec to convert the loans to
shares of HeartWare common stock have been extinguished.
About HeartWare International - HeartWare International develops and manufactures
miniaturized implantable heart pumps, or left ventricular assist devices, to treat Class IIIb and
Class IV patients suffering from advanced heart failure. The HeartWare Ventricular Assist
System features the HVAD pump, a small full-output circulatory support device (up to 10L/min
flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally
required to implant competing devices. HeartWare has received CE Marking for the HeartWare
Ventricular Assist System in the European Union. The device is currently the subject of a 150-
patient clinical trial in the United States for a Bridge-to-Transplant indication.
HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly
traded on The NASDAQ Stock Market.